Anesthetic management of patients with polycythemia vera. Case presentation
Keywords:
polycythemia vera, myeloproliferative neoplasms, thrombosis, anesthetic managementAbstract
Introduction: Polycythemia vera, or Vaquez-Osler disease, belongs to the group of myeloproliferative neoplasms and presents clinical and analytical characteristics such as persistent leukocytosis and thrombocytosis, microcytosis secondary to iron deficiency, increased red blood cell mass, JAK2 mutations, increased leukocyte alkaline phosphatase, splenomegaly, generalized aquagenic pruritus, bleeding, arterial and venous thrombosis, including in unusual locations, and erythromegaly.
Patient presentation: This report describes the anesthetic management of a patient in whom the main considerations are related to increased blood viscosity, which leads to a higher risk of thrombosis and a greater incidence of atherosclerosis and heart disease.
Conclusions: The discontinuation of aspirin and hydroxyurea, the pre- and postoperative use of low molecular weight heparin, acute normovolemic hemodilution, adequate hydration, the use of elastic stockings on lower limbs, early ambulation, good surgical hemostasis, and the availability of blood and its components are the fundamental elements in the management of this patient.
Downloads
References
1. Tefferi A. Policitemia Vera, Trombocitemia Esencial y Mielofibrosis Primaria. En: Goldman L, Schafer AI.Tratado de Medicina Interna. 25 ed. Barcelona: Elsevier; 2017. p. 1122-1128.
2. Oprea AD. Hematologic disorders. En: Hines RL, Marshall KE. Stoelting`s Anesthesia and co-existing diseases. 7a ed. Philadelphia: Elsevier; 2018. p. 477-506.
3.- Wijeysundera DN, Sweitzer BJ. Evaluación preoperatoria. En: Miller RD. Anestesia. 8a ed. Barcelona: Elseivier; 2016. p. 1085-1155.
4. Thiele J, Kvesnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, et al. The international consensusclassification of myeloid neoplasms and acute leukemia: myeloproliferative neoplasms. Am J Hematol [Internet]. 2023 [citado 23/07/2025]; 98(3): [aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36200127/
https://doi.org/10.1002/ajh.26821
5. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvsnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphologic, clinical and genomic data. Blood. [Internet]. 2022 [citado 23/07/2025]; 140(11): [aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35767897/
https://doi.org/10.1182/blood.2022015850
6. Orazi A, Hasserjian RP, Cazzola M, Dohuer H, Tefferi A, Arber DA. International consensus for myeloid neoplasms at-a-glane. Am J Hematol [Internet]. 2023 [citado 23/05/2025]; 98(1):[aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36314608/
https://doi.org/10.1002/ajh.26772
7. Tefferi A, Vannucchi AM, Barbui T. Polycythemia Vera: historical oversights, diagnostic details and therapeutic views. Leukemia [Internet]. 2021 [acceso 23/07/2025]; 35: [aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34480106/
https://doi.org/10.1038/s41375-021-01401-3
8. Tefferi A, Barbui T. Policitemia Vera: actualizacion de 2024 sobre diagnostico, estratificacion de riesgo y tratamiento. Am J Hematol [Internet]. 2023 [citado 23/07/2025]; 98(9): [aprox. 2p.]. Disponible en: https://pubmed-ncbi-nlm-nih-gov.translate.goog/37357958/
https://doi.org/10.1002/ajh.27002
9. Tefferi A, Barbui T. Polycythemia Vera and Essential Thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol [Internet]. 2020 [citado 23/07/2025]; 95(12): [aprox. 3p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32974939/
https://doi:10.1002/ajh.26008
10. Cruz García O, Nieto Monteagudo CG, Álvarez Hurtado LM, Cruz Hernández Y, Cruz Hernández M. Manejo anestésico en pacientes con Trombocitemia esencial. Rev Cubana Anestesiología Reanimación [Internet]. 2021 [citado 22/07/2025]; 20(3): [aprox. 2p.]. Disponible en: http://www.revanestesia.sld.cu/index.php/anestRean/article/view/729
11. Chang L, Li WX, Cai H, Li J, Duan MH. Efficacy and safety of pegylated interferon in the treatment of JAK2 V617F-positive Polycythemia Vera with a dose de-escalation strategy: a single center retrospective study. Front Oncol [Internet]. 2025 [citado 23/07/2025]; 15: [aprox. 2p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/40438689/
https://doi.org/10.3389/fonc.2025.1586839
12. Marjoncu D, Carmichael J, Andrick BJ, Oxemberg J. Stopping Oral Chemotherapy Agents With a High Bleeding Risk Before and After Minor Surgical Procedures. J Hematol Oncol Pharm [Internet]. 2023 [citado 22/07/2025]; 13(3): [aprox. 3p.]. Disponible en: https://www.jhoponline.com/online-first/19522-stopping-oral-chemotherapy-agents-with-a-high-bleeding-risk-before-and-after-minor-surgical-procedures
13. Jianli Z, Liang H, Matson D, Na L, Lin H. Perioperative management of polycythemia. En: Scher CS. Essential of blood product management in anesthesia practice. 1ra ed. Nueva York: Springer; 2021 [citado 22/07/2025]. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-59295-0_42
14. Cherenfant C, Umeth U. Coagulation and regional anesthesia. En: Scher CS. Essential of blood product management in anesthesia practice. 1ra ed. Nueva York. Springer; 2021 [citado 22/07/2025]. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-59295-0_44
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Osmany Cruz García, Carlos Gilberto Nieto Monteagudo, Miguel Alejandro Guerra Hernández

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).




january 1, 2026